FDA Orange Book · active-ingredient family
Brimonidine tartrate; brinzolamide
Brimonidine tartrate; brinzolamide is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:SIMBRINZA · NDA 204251
1
Brand (NDA)
0
Generics (ANDA)
2
Listed patents
0
Exclusivity periods
Brand (NDA) products · suspension/drops
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SIMBRINZARLD | ALCON LABS INC | NDA 204251 | — | Apr 19, 2013 |
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9421265 | Jun 17, 2030 | in 4 yr 1 mo | Product |
| 9044484 | Oct 30, 2030 | in 4 yr 5 mo | Product |
Brimonidine tartrate; brinzolamide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
